Surgical resection is the election treatment for non-small cell lung cancer (NSCLC), although it is not always possible. Platinum-based chemotherapy, with or without maintenance therapy and followed by second-line cytotoxic chemotherapy, is the standard treatment for most patients with advanced NSCLC, with a median survival of about one year. In the last 30 years, a large number of studies have focused on the molecular mechanisms of the cisplatin-resistant phenotype of tumor cells, which could provide crucial information for treatment resensitization.
This project arises from the data previously obtained by two research groups (Institutes of Health Research IdiPAZ and IRYCIS) that unified their efforts in the selection of aptamers against the Transcription factor MAFG as a prognostic marker of resistance to the chemotherapeutic drugs in lung cancer. Both groups carried out studies that link the regulation of the gene that encodes the MAFG1 protein with the response to cisplatin chemotherapy in NSCLC, postulating it as a potential new therapeutic target for tumors of this type resistant to cisplatin. Together with the companies Aptus and Atrys, the main objective of the consortium is to use the Transcription Factor MAFG as a predictive marker of response to treatment with platinum derivatives developing prognostic tools based on aptamers. For this, it is intended to develop two prognostic kits, based on aptahistochemistry and liquid biopsy for the determination of the levels of the MAFG marker as a prognosis of resistance to platinum derivatives in patients with lung cancer.